| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Division of Immunopathology, Institute of Pathology, and
Department of Clinical Research, University of Bern, Bern, Switzerland;
GI Division, Department of Medicine, Northwestern Medical School, Chicago, IL 60611; and
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
Fas (CD95/APO-1) ligand (FasL)-mediated cytotoxicity has been implicated in tissue destruction in a variety of diseases, including acute graft-vs-host disease (GVHD). In this study, we have analyzed FasL expression and regulation during the course of experimental murine acute GVHD. Although activation-induced FasL-mediated cytotoxicity in control T cells was sensitive to the immunosuppressant cyclosporin A, we observed that functional FasL expression of GVHD T cells became increasingly cyclosporin A unresponsive. This was found to be the result of a massive in vivo accumulation and intracellular storage of FasL protein and its release in a transcription- and protein synthesis-independent manner. Immunohistochemistry analysis of FasL expression in situ revealed accumulation of FasL-expressing cells in the spleen, the liver, and small intestine, with a typical cytoplasmic and granular expression pattern. Thus, we conclude that the release of preformed FasL by infiltrating donor T cells may contribute to recipient tissue damage during the pathogenesis of acute GVHD.
This article has been cited by other articles:
|
|
 |
|
  T. Ramirez-Montagut, A. Chow, A. A. Kochman, O. M. Smith, D. Suh, H. Sindhi, S. Lu, C. Borsotti, J. Grubin, N. Patel, et al. IFN-{gamma} and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease J. Immunol., August 1, 2007; 179(3): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Nachbur, D. Kassahn, S. Yousefi, D. F. Legler, and T. Brunner Posttranscriptional regulation of Fas (CD95) ligand killing activity by lipid rafts Blood, April 1, 2006; 107(7): 2790 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Torgler, S. Jakob, E. Ontsouka, U. Nachbur, C. Mueller, D. R. Green, and T. Brunner Regulation of Activation-induced Fas (CD95/Apo-1) Ligand Expression in T Cells by the Cyclin B1/Cdk1 Complex J. Biol. Chem., September 3, 2004; 279(36): 37334 - 37342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sostak, P. Reich, C. S. Padovan, A. Gerbitz, E. Holler, and A. Straube Cerebral Endothelial Expression of Adhesion Molecules in Mice with Chronic Graft-Versus-Host Disease Stroke, May 1, 2004; 35(5): 1158 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Rao, M. P. Quinones, E. Garavito, Y. Kalkonde, F. Jimenez, C. Gibbons, J. Perez, P. Melby, W. Kuziel, R. L. Reddick, et al. CC Chemokine Receptor 2 Expression in Donor Cells Serves an Essential Role in Graft-versus-Host-Disease J. Immunol., November 1, 2003; 171(9): 4875 - 4885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Akpek, J. K. Boitnott, L. A. Lee, J. P. Hallick, M. Torbenson, D. A. Jacobsohn, S. Arai, V. Anders, and G. B. Vogelsang Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion Blood, December 1, 2002; 100(12): 3903 - 3907. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
